Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies ... zimberelimab and chemotherapy achieved “encouraging” response and progression-free ...

Preliminary immunogenicity results showed that the vaccine induced cancer antigen-specific T-cell responses in 10 of 13 evaluable patients (77%), which is "very encouraging," Tabatabai said.

3 "These new data could represent positive news in the future treatment of non-small cell lung cancer patients with activating HER2 mutations," said the trial’s principal investigator ...

plus Nivolumab and CAPOX as the first-line treatment for the patients with advanced G/GEJ cancer (TranStar102). The updated data continues to show encouraging efficacy from previously disclosed ...

3 "These new data could represent positive news in the future treatment of non-small cell lung cancer patients with activating HER2 mutations," said the trial's principal investigator, Dr. John ...

Using the group of patients with very low or no ... and CAPOX as first-line treatment for advanced G/GEJ cancer are highly encouraging. The confirmed objective response rate and median progression ...